FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 453 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 A New FDA Approval Furthers the Role of Genomics in Cancer... July 8, 2020 Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... December 8, 2020 FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer July 4, 2025 Load more HOT NEWS FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People Young Women At Increased Risk Of Aggressive Breast Cancer ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers...
